NEW YORK, NY, Apr 09, 2013 (Marketwired via COMTEX) — PropThink.com, a leading healthcare-focused provider of investment research and analysis, will host a conference call with Intellectual Property attorney and former associate solicitor for the U.S. Patent and Trademark Office (USPTO), Dr. Scott Chambers. PropThink has engaged Dr. Chambers to evaluate the existing Intellectual Property for Zerenex, Keryx Biopharmaceuticals’ phosphate binder for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients on dialysis. The strength of Zerenex’s IP estate has been a point of debate since Keryx released Phase III clinical trial results in January of 2013, resulting in uncertainty within the investing community regarding Keryx’s ability to protect Zerenex from generic challengers. The emergence of this controversy has caused shares of Keryx to shed roughly 30% off of their highs from earlier this year, and as a result PropThink believes that clarity on this issue, specifically in relation to Zerenex obtaining a Patent Term Extension, will provide investors with valuable and actionable information about Zerenex’s long-term market opportunity. On PropThink’s upcoming conference call, Dr. Chambers will offer his professional opinion regarding Patent Term Extension for Zerenex, and will develop insight into the overall strength of Zerenex’s existing patents.
The call will take place on Thursday, April 11 at 11:00AM EDT, will feature a discussion with Dr. Chambers, and will also include a Question and Answer session for participants. The call is open to members of PropThink’s Premium Subscription service, and interested parties can sign up for a free 30-day trial membership by clicking here. We believe that this call will offer valuable insight for biotech investors, specifically those interested in Keryx Biopharmaceuticals and the future of Zerenex.
Dr. Chambers serves as chair of the Intellectual Property Department for the offices of Patton Boggs’, a leading international law firm located in Washington D.C. with a focus on Public Policy and Business Law. Dr. Chambers formerly served as an associate solicitor for the USPTO, where he defended the Office’s patentability determinations and statutory interpretation before the U.S. Court of Appeals for the Federal Circuit and district court. In his tenure at the USPTO, Dr. Chambers played a role in determining Patent Term Extension for various drug products. He has also drafted Examination Guidelines for the Examining Corps of the USPTO and congressional testimony for the agency regarding biotechnology and patents. Dr. Chambers has served as a frequent speaker on behalf of the USPTO and is a member of the Editorial Board of the Biotechnology Law Report, an advisory Board member for the Patent Trademark and Copyright Journal, and IP Law 360.